ArticleBMC cancer2018
Inflammation marker ESR is effective in predicting outcome of diffuse large B-cell lymphoma.
Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association of inflammatory markers with the severity of COVID-19: A meta-analysis.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2020Pooled it
- Natural Killer T Cell Function in Lymphoma Patients.Biomolecules · 2026Article
- Integrating chronic inflammation and hypoxia: the potential role of HIF-1α in tumor behavior and therapy response in high-grade serous ovarian cancer.Frontiers in immunology · 2026Article
- The Erythrocyte Sedimentation Rate as a Novel Prognostic Marker in Canine Inflammatory Diseases.Animals : an open access journal from MDPI · 2025Article
- Hypoalbuminemia, but not derived neutrophil to lymphocyte ratio (dNLR), predicts overall survival in neuroendocrine tumours undergoing peptide receptor radionuclide therapy: A retrospective, cohort study of 557 patients.Journal of neuroendocrinology · 2025Article
- Assessment of COVID-19 patients' outcome based on clinical profile, laboratory parameters, and clinical management: A retrospective observational study.Journal of family medicine and primary care · 2024Article
- Predictive Value of CorrectedWorld journal of nuclear medicine · 2024Article
- The Role of Erythrocyte Sedimentation Rate (ESR) in Myeloproliferative and Lymphoproliferative Diseases: Comparison between DIESSE CUBE 30 TOUCH and Alifax Test 1.Diseases (Basel, Switzerland) · 2023Article
- Assessing serum C-reactive protein as a predictor of COVID-19 outcomes: a retrospective cross-sectional study.Annals of medicine and surgery (2012) · 2023Article
- Effect of storage temperature and time on erythrocyte sedimentation rate.European journal of medical research · 2022Article
- Erythrocyte sedimentation rate, C-reactive protein, and interleukin-6 as inflammatory biomarkers in dogs naturally infected withVeterinary world · 2021Article
- The dynamics of inflammatory markers in coronavirus disease-2019 (COVID-19) patients: A systematic review and meta-analysis.Clinical epidemiology and global healthReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundSystemic inflammation has been implicated in cancer development and progression. This study examined the best cutoff value of erythrocyte sedimentation rate (ESR) in diffuse large B-cell lymphoma (DLBCL) patients.
methodsThe relationship between ESR and clinical characteristics was analyzed in 182 DLBCL patients from 2006 to 2017. The log-rank test, univariate analysis, and Cox regression analysis were applied to evaluate the relationship between ESR and survival. An ESR of more than 37.5 mm/hour was found to be the optimal threshold value for predicting prognosis.
resultsESR was associated with more frequent advanced Ann Arbor stage, poorer performance status, elevated lactate dehydrogenase level, the presence of B symptoms, high-risk International Prognostic Index (IPI 3-5), more extranodal involvement (ENI ≥2), non-germinal-center B-cell (non-GCB) subtypes, and more frequent Myc protein positivity. Shorter overall survival (OS) and progression-free survival (PFS) were found for patients with higher ESRs. Multivariate analysis demonstrated that ESR level is an independent prognostic factor of both OS and PFS. In addition, dynamic changes in ESR are valuable in assessing curative effect and predicting disease recurrence.
conclusionHigh ESR in DLBCL patients indicated unfavorable prognosis that may require alternative treatment regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.